Sameer Shaharyar1, Haider Warraich2, John W McEvoy3, Ebenezer Oni1, Shozab S Ali1, Adil Karim1, Omar Jamal1, Michael J Blaha3, Roger S Blumenthal3, Jonathan Fialkow4, Ricardo Cury5, Matthew J Budoff6, Arthur A Agatston1, Khurram Nasir7. 1. Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, FL, USA. 2. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. 4. Baptist Hospital of Miami and Baptist Cardiac & Vascular Institute, Miami, FL, USA. 5. Baptist Hospital of Miami and Baptist Cardiac & Vascular Institute, Miami, FL, USA; Department of Radiology, Florida International University, Miami, FL, USA. 6. Los Angeles Biomedical Research Institute, UCLA Harbor Medical Center, CA, USA. 7. Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, FL, USA; Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA; The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Baptist Hospital of Miami and Baptist Cardiac & Vascular Institute, Miami, FL, USA; Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, FL, USA. Electronic address: KhurramN@baptisthealth.net.
Abstract
BACKGROUND: Psoriasis patients have a high prevalence of cardiovascular events and are thought to have a relative risk increase of 25% as compared to the general population. However, a causal relationship between psoriasis and cardiovascular disease has not been established. We sought to perform a systematic review of existing data regarding the presence of endothelial dysfunction and subclinical atherosclerosis in patients with plaque psoriasis. METHODS: A systematic literature search was performed, using Medline database and Ovid SP for relevant literature up to November 2012. Twelve studies met inclusion criteria from an initial search result of 529 articles. RESULTS: Among the twelve studies meeting inclusion criteria, two (17%) reported increased mean coronary artery calcification (CAC) in psoriatic patients. Six studies (50%) showed carotid intima-media thickness [CIMT] increase in psoriasis. Five studies (42%) examined flow mediated dilation [FMD], of which three showed decreased FMD in psoriasis patients. One study (8%) each demonstrated a decreased coronary flow reserve and increased arterial stiffness as assessed by pulse wave velocity. CONCLUSIONS: Patients with psoriasis have an increased burden of subclinical atherosclerosis and endothelial dysfunction. Patients with greater severity and/or disease duration should be targeted for primary screening for cardiovascular disease risk reduction.
BACKGROUND:Psoriasispatients have a high prevalence of cardiovascular events and are thought to have a relative risk increase of 25% as compared to the general population. However, a causal relationship between psoriasis and cardiovascular disease has not been established. We sought to perform a systematic review of existing data regarding the presence of endothelial dysfunction and subclinical atherosclerosis in patients with plaque psoriasis. METHODS: A systematic literature search was performed, using Medline database and Ovid SP for relevant literature up to November 2012. Twelve studies met inclusion criteria from an initial search result of 529 articles. RESULTS: Among the twelve studies meeting inclusion criteria, two (17%) reported increased mean coronary artery calcification (CAC) in psoriaticpatients. Six studies (50%) showed carotid intima-media thickness [CIMT] increase in psoriasis. Five studies (42%) examined flow mediated dilation [FMD], of which three showed decreased FMD in psoriasispatients. One study (8%) each demonstrated a decreased coronary flow reserve and increased arterial stiffness as assessed by pulse wave velocity. CONCLUSIONS:Patients with psoriasis have an increased burden of subclinical atherosclerosis and endothelial dysfunction. Patients with greater severity and/or disease duration should be targeted for primary screening for cardiovascular disease risk reduction.
Authors: Marco D'Agostino; Sara Beji; Sara Sileno; Daniela Lulli; Laura Mercurio; Stefania Madonna; Corrado Cirielli; Sabatino Pallotta; Cristina Albanesi; Maurizio C Capogrossi; Daniele Avitabile; Guido Melillo; Alessandra Magenta Journal: Front Cardiovasc Med Date: 2022-04-28
Authors: Manja Koch; Hansjörg Baurecht; Janina S Ried; Elke Rodriguez; Sabrina Schlesinger; Natalie Volks; Christian Gieger; Ina-Maria Rückert; Luise Heinrich; Christina Willenborg; Catherine Smith; Annette Peters; Barbara Thorand; Wolfgang Koenig; Claudia Lamina; Henning Jansen; Florian Kronenberg; Jochen Seissler; Joachim Thiery; Wolfgang Rathmann; Heribert Schunkert; Jeanette Erdmann; Jonathan Barker; Rajan P Nair; Lam C Tsoi; James T Elder; Ulrich Mrowietz; Michael Weichenthal; Sören Mucha; Stefan Schreiber; Andre Franke; Jochen Schmitt; Wolfgang Lieb; Stephan Weidinger Journal: J Invest Dermatol Date: 2015-01-19 Impact factor: 8.551
Authors: Balázs Németh; Iván Péter; Imre Boncz; Anna Jagicza; István Kiss; Ágnes Csergő; Tamás Kőszegi; Péter Kustán; Iván G Horváth; Zénó Ajtay Journal: Ther Clin Risk Manag Date: 2019-07-05 Impact factor: 2.423
Authors: S Santilli; D R Kast; I Grozdev; L Cao; R L Feig; J B Golden; S M Debanne; R C Gilkeson; C E Orringer; T S McCormick; N L Ward; K D Cooper; N J Korman Journal: J Transl Med Date: 2016-07-22 Impact factor: 5.531
Authors: Jackelyn B Golden; Yunmei Wang; Yi Fritz; Doina Diaconu; Xiufen Zhang; Sara M Debanne; Daniel I Simon; Thomas S McCormick; Nicole L Ward Journal: J Transl Med Date: 2015-12-16 Impact factor: 5.531